Therapy optimisation trial for the treatment of Ewing sarcoma

Ewing sarcoma is the second most common type of childhood bone cancer. To date, there is no standard therapy for the treatment of recurrent and primary refractory Ewing sarcoma.

Aim of the trial

The rEECur trial involves comparing different chemotherapies with established drugs with one another. The results are constantly analysed so that therapies that work less well can be removed from the trial and new ones added. The aim of this trial is to identify the best therapy for the treatment of recurrent and primary refractory Ewing sarcomas in terms of the survival rate and toxicity. Another goal is to improve the patients’ quality of life. In Switzerland, the Swiss Paediatric Oncology Group (SPOG) is responsible for the organisation and implementation of the international trial.

Implementing organisation 

Swiss Paediatric Oncology Group (SPO